The prescription of Tong Xie Yao Fang (TXYF) was derived from the Yuan dynasty "Dan Brook Heart Law," which was a representative formula for treating liver-spleen disharmony, diarrhea, and abdominal pain. The prescription is composed of four herbs for soothing the liver and strengthening the spleen. TXYF is reportedly capable of eliminating discomfort in ulcerative colitis (UC). This classic formula has been widely used for regulating gastrointestinal motor dysfunction and repairing colon mucosa. This review aims to provide current information on the pharmacology and clinical research of TXYF in the treatment of UC, and to critically appraise that information, in order to guide the future clinical use and experimental study of TXYF in the treatment of UC. We searched online databases including PubMed, CNKI, and Google Scholar for research published between 2010 and 2020 on TXYF and its efficacy in the treatment of UC. The findings indicated that TXYF has anti-inflammatory and immunomodulatory effects, regulates cell signal transduction, brain-gut axis, and intestinal flora in UC, and may promote targeting of bone mesenchymal stem cells (BMSCs) to the colonic mucosa and accelerate healing of the colonic mucosal barrier. In addition, the results of clinical studies showed that TXYF has good efficacy and few adverse reactions in the treatment of UC. Although it has achieved some success, the research is limited by deficiencies; there is a lack of unified standards for the construction of UC animal models and for administration regimen. In addition, the dosage of TXYF is not consistent and lacks pharmacological verification, and clinical trial data are not detailed or sufficiently rigorous. Therefore, a more rigorous, comprehensive, and in-depth study of TXYF in the treatment of UC is needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208878 | PMC |
http://dx.doi.org/10.1155/2021/5548764 | DOI Listing |
BMJ Open
January 2025
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
Objectives: To assess the therapeutic effects and safety of Tongxie Yaofang (TXYF) granules vs placebo as an alternative treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). We hypothesised that TXYF would improve clinical responses among patients with IBS-D.
Design: A randomised, double-blind, placebo-controlled, phase II, superiority trial.
Front Cell Infect Microbiol
December 2024
Research and Development Center, Kangpu Pharmaceutical Co., Ltd., Changde, Hunan, China.
Background: Tongxieyaofang (TXYF) was a traditional Chinese medicine (TCM) formula for the treatment of diarrhea with liver stagnation and spleen deficiency syndrome, but the potential targets and mechanisms have not been fully clarified. This study aims to explore the potential mechanisms of TXYF in alleviating diarrhea using network pharmacology and full-length 16S rRNA gene sequencing.
Methods: Network pharmacology was applied to identify bioactive compounds and potential targets involved in the role of TXYF in alleviating diarrhea.
Phytomedicine
January 2025
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address:
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease closely related to gut microbiota dysbiosis and intestinal homeostasis imbalance. Sishen Pill&Tongxieyaofang (SSP-TXYF) has a long history of application in traditional Chinese medicine and is widely used in UC clinics. However, its mechanism of action is still unclear.
View Article and Find Full Text PDFTongxie Yaofang (TXYF), a classical traditional Chinese medicine, is commonly used in China to treat ulcerative colitis (UC). The aim of this study was to integrate network pharmacology with molecular docking and molecular dynamics simulations to explore the mechanism of Tongxie Yaofang in the treatment of UC. The traditional Chinese medicine systems pharmacology database was used to retrieve the relevant chemical compositions of the herbs contained in TXYF.
View Article and Find Full Text PDFDrug Des Devel Ther
July 2024
Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310003, People's Republic of China.
Purpose: Through network pharmacology combined with molecular docking and in vivo validation, the study examines the unexplored molecular mechanisms of Tongxieyaofang (TXYF) in the treatment of irritable bowel syndrome (IBS). In particular, the potential pharmacological mechanism of TXYF alleviating IBS by regulating CHRM3 and intestinal barrier has not been studied.
Patients And Methods: LC-MS technique and TCMSP database were used in combination to identify the potential effective components and target sites of TXYF.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!